Health Canada Seeks Alcohol Interaction Data For Slow-Release Opioids
This article was originally published in The Pink Sheet Daily
Executive Summary
Manufacturers have six months to submit data on potential dose dumping due to interaction with alcohol.
You may also be interested in...
Purdue Signs On To Market Labopharm's Once-Daily Tramadol
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.
Purdue Signs On To Market Labopharm's Once-Daily Tramadol
Labopharm will receive up to $170 mil. under the licensing deal, including $20 mil. up front and $40 mil. upon NDA approval.
FDA Requests Strengthened Warnings For Extended-Release Morphine Avinza
The labeling change request coincides with the withdrawal of Purdue's extended-release hydromorphone product Palladone due to the potential for serious alcohol-related adverse events. Ligand will intensify warnings about alcohol use with Avinza while further information on the risk is gathered.